$19.46
0.864.62%
Last update: Nov 9, 4:00 PM
Braveheart Bio Inc
BRVENASDAQ
Braveheart Bio fell 34.7% from $29.80 to $19.46, behind the S&P 500's −2.1%. Its worst day was Sep 21 (−14.3%), and its low came Nov 5 at $17.42.
Aug 6, 2026 – Nov 9, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Braveheart Bio closed at its highest level of the year, 0.7% above where the year started.
+0.7% · S&P 500 +0.6%
EPS of $-2.51 missed the $0.74 estimate on $0.00 revenue.
−1.7% · S&P 500 −0.5%
Story events cover the past 12 months · Times ET
Braveheart Bio shares fell 14.3%, while the S&P 500 rose 1.6%.
−14.3%, the year's worst day · S&P 500 +1.6%
Where it ended: a close of $19.46 on Nov 9, 2026. Up next: Q3 2026 earnings on Nov 23, 2026 (EPS est. $-0.53).
Nothing in the past 12 months.
All BRVE dividend historyChart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for BRVE and SPY from Benzinga historical bars. Not investment advice.
